Hypertension, Pulmonary Clinical Trial
— HEXASNOfficial title:
Hemodynamic Effects of Acute Normobaric Hypoxia During Exercise in Patients With Pulmonary Hypertension: Single-center Randomized Controlled Trial
Verified date | May 2022 |
Source | University of Zurich |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To study hemodynamic effects of Sildenafil during exercise in patients with pulmonary hypertension.
Status | Completed |
Enrollment | 24 |
Est. completion date | May 31, 2023 |
Est. primary completion date | May 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Informed consent as documented by signature (Appendix Informed Consent Form) - PH class I (PAH) or IV (CTEPH) diagnosed according to guidelines: mean pulmonary artery pressure >20 mmHg, pulmonary vascular resistance =3 wood units, pulmonary arterial wedge pressure =15 mmHg during baseline measures at the diagnostic right-heart catheterization Exclusion Criteria: - resting partial pressure of oxygen <8 kilopascal at Zürich altitude on ambient air - exposure to an altitude >1000 m for =3 nights during the last 2 weeks before the study - inability to follow the procedures of the study - patients who take nitrates - other clinically significant concomitant end-stage disease (e.g., renal failure, hepatic dysfunction) |
Country | Name | City | State |
---|---|---|---|
Switzerland | UniversityHospital Zurich, Department of Pulmonology | Zurich | |
Switzerland | University Hospital of Zurich | Zürich | Zurich |
Lead Sponsor | Collaborator |
---|---|
University of Zurich |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | mean pulmonary artery pressure (mPAP) / cardiac output (CO) | Difference in mPAP/CO during exercise between tests under normoxia with/without Sildenafil | 4 hours | |
Secondary | Differences in pulmonary arterial pressure | Differences in pulmonary arterial pressure at rest and during exercise under normoxia with/without Sildenafil | 4 hours | |
Secondary | Differences in cardiac output | Differences in cardiac output at rest and during exercise under normoxia with/without Sildenafil | 4 hours | |
Secondary | Differences in pulmonary vascular resistance | Differences in pulmonary vascular resistance at rest and during exercise under normoxia with/without Sildenafil | 4 hours | |
Secondary | Differences in pulmonary artery wedge pressure | Differences in pulmonary artery wedge pressure at rest and during exercise under normoxia with/without Sildenafil | 4 hours | |
Secondary | Differences in right atrial pressure | Differences in right atrial pressure at rest and during exercise under normoxia with/without Sildenafil | 4 hours | |
Secondary | Differences in mixed venous oxygen saturation | Differences in mixed venous oxygen saturation at rest and during exercise under normoxia with/without Sildenafil | 4 hours | |
Secondary | Differences in heart rate | Differences in heart rate at rest and during exercise, under normoxia with/without Sildenafil | 4 hours | |
Secondary | Differences in blood pressure (systolic and diastolic) | Differences in blood pressure (systolic and diastolic) at rest and during exercise, under normoxia with/without Sildenafil | 4 hours | |
Secondary | Differences in oxygen saturation | Differences in oxygen saturation at rest and during exercise, under normoxia with/without Sildenafil | 4 hours | |
Secondary | Differences in arterial blood gases | Differences in arterial blood gases at rest and during exercise under normoxia with/without Sildenafil | 4 hours | |
Secondary | Differences in mixed venous blood gases | Differences in mixed venous blood gases at rest and during exercise under normoxia with/without Sildenafil | 4 hours | |
Secondary | Differences in cerebral tissue oxygenation | Differences in cerebral tissue oxygenation at rest and during exercise, under normoxia with/without Sildenafil | 4 hours | |
Secondary | Differences in muscle tissue oxygenation | Differences in muscle tissue oxygenation at rest and during exercise, under normoxia with/without Sildenafil | 4 hours | |
Secondary | Differences in symptoms (Borg dyspnoea) | Differences in symptoms (Borg dyspnoea, Borg CR10, scale 0-10) at rest and during exercise under normoxia with/without Sildenafil | 4 hours | |
Secondary | Differences in symptoms (leg effort) | Differences in symptoms (leg effort, scale 0-10, 10 is maximal exhaustion) at rest and during exercise under normoxia with/without Sildenafil | 4 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04095286 -
Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult Participants
|
Phase 1 | |
Enrolling by invitation |
NCT03683186 -
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
|
Phase 3 | |
Completed |
NCT02191137 -
Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)
|
Phase 4 | |
Completed |
NCT01959828 -
Confirmatory Study of IK-3001 in Japanese Subjects With Peri-/Post-op Pulmonary Hypertension Assoc. With Cardiac Surgery
|
Phase 3 | |
Withdrawn |
NCT01202045 -
Stress Echocardiography in the Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis Patients
|
N/A | |
Completed |
NCT00963027 -
Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil
|
Phase 1 | |
Completed |
NCT00963001 -
Effect of Food on the Pharmacokinetics of Oral Treprostinil
|
Phase 1 | |
Completed |
NCT01121458 -
Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed
|
Phase 4 | |
Terminated |
NCT00825266 -
Insulin Resistance in Pulmonary Arterial Hypertension
|
Phase 4 | |
Terminated |
NCT00384865 -
A Study of Aspirin and Simvastatin in Pulmonary Arterial Hypertension
|
Phase 2 | |
Active, not recruiting |
NCT03926572 -
Acute Decompensation of Pulmonary Hypertension
|
N/A | |
Completed |
NCT02826252 -
Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20)
|
N/A | |
Completed |
NCT02545465 -
A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice
|
N/A | |
Recruiting |
NCT04498299 -
Stress Echocardiography in Patients Recovery From Mild COVID-19 Illness
|
||
Recruiting |
NCT02558582 -
Effect of Exercise Training in Patients With Pulmonary Hypertension
|
N/A | |
Active, not recruiting |
NCT02562235 -
Riociguat in Children With Pulmonary Arterial Hypertension (PAH)
|
Phase 3 | |
Completed |
NCT02755298 -
Chronic Clinical Effect of Acetazolamide
|
Phase 2/Phase 3 | |
Terminated |
NCT03043976 -
Using Step Count to Enhance Daily Physical Activity in Pulmonary Hypertension
|
N/A | |
Completed |
NCT02576002 -
Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension)
|
N/A | |
Completed |
NCT01317134 -
Endothelial Function in Patients With Pulmonary Arterial Hypertension
|
N/A |